Background:
- Plasma cells producing amyloidogenic light chains are highly sensitive to proteasome inhibition1
- Bortezomib has high response rates in relapsed AL amyloidosis2
- Carfilzomib is a novel, irreversible proteasome inhibitor active in multiple myeloma, with less neurotoxicity3
- The safety and efficacy of carfilzomib in patients with AL is not known
Used by permission: Adam D. Cohen, MD, University of Pennsylvania